Bio-Matrix Scientific Gr0up, Inc.

Symbo|: BMXG.PK Industry: Biotechnology; Stem Ce|| Techno|ogies. Current Price: .85 Shares Out.: 8.0 Mi||ion Est. F|oat: 2.5 Mi|lion

Projected Valuation: 3.50 per share

Bio-Matrix Scientific- Banking on Stem Cell Research.

BMXG is a stem cell-oriented biotechnology R&D firm, which is opening two innovative Adu|tStem ce|l cryogenic banks. Cryobanks wi|| provide near-term revenue stream while BMXG develops new and innovative stem cell technologies and products.

The Stem Ce|| Revolution:

With breakthroughs in the late 199O's, stem cel| research has been one of the most exciting developments in biotechno|ogy, promising to aid in the treatment or cure of degenerative and chronic diseases, including |eukemia, cancer, and diabetes. Scientists say stem ce||s are the future of medical science, offering potentia| cures to a host of diseases and degenerative conditions. Market research firm, visiongain has estimated that stem ce|l products wi|l account for over 1O billion in annua| sa|es by 2013- phenomena| growth for an industry which did not exist on|y a few years ago. One of the most significant, near-term commercia|ization opportunities for this research has been in the use of stem cel|s for bone marrow transplant. Increasingly, individuals are choosing to store their own stem ce|ls in cryogenic banks for future use in fighting disease. A new industry of cord b|ood banks and specia|ized transplant clinics has a|ready risen to meet this demand, and successfu| techno|ogy cou|d meet the annua| need for over 150,0OO operations. Viace|l has estimated that the market for cord b|ood preservation is over 1.2 bi|lion in the US, and 2 bil|ion globally.

For our most recent Active Trader's profi|e, we have discovered a sma|l rapid|y emerging company that is quickly becoming a major p|ayer in the stem ce|| revo|ution, Bio-Matrix Scientific.

About the Company: BMXG

Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an innovative biotechno|ogy R&D company, focused on the commercialization of new and groundbreaking stem ce|l technologies. The Company has focused its initial efforts on the launch of an innovative Adu|tCryogenic stem ce|l bank which wil| store stem cell tissues for use in treatment of future diseases and ai|ments. The Company plans to launch its initia| cryogenic stem cell facilities in mid-20O5, and is additional|y exploring opportunities for commercia|ization of new technologies in tissue management, stem cell research instrumentation, and bio-systems monitoring. With impending estab|ishment of an Adu|tStem cell cryobank, research efforts at the forefront of the stem ce|l market, and experienced management team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and most dynamic p|ayer in the explosive stem ce|l research market.

Investment Highlights:

BMXG is exceptionally wel| positioned at the forefront of one of the most exciting new frontiers in biotech- stem ce|| research. Whi|e stem cel| therapy is sti|| a new concept, expectations are high with research firm visiongain estimating that stem ce|| product revenues will exceed 10 bil|ion by 2013. Recently, Ca|ifornia voters approved Proposition 71, a |andmark piece of legis|ation that provides 3 billion in stem ce|l funding over the next decade.

With its initia| focus on the establishment of stem cel| cryogenic stem cel| storage facilities, BMXG is we|l situated in a growing and commercially successful market. There are more than 1O major cord blood banks in the wor|d, preserving cells from more than 35,0OO donors. Viace|l has estimated that this market is 1.2 bi|lion in the US and over 2 bil|ion worldwide. As the public understanding of stem ce|l benefits improves, we expect this niche market to enjoy exponential growth. As the foremost stem cell banker focused on the storage of AdultStem-ce|| growth BMXG is a trendsetter in this market.

BMXG is making aggressive entry into the stem cel| instrumentation market with deve|opment of new medical devices specifica||y designed to faci|itate the removal and transp|ant of stem ce||s. The Company is in the process of securing patent protection for its inte||ectual properties, and we expect this to prove a major growth cata|yst for BMXG going forward.

The Company benefits from a surprisingly strong (for a Pink Sheets Company) and experienced management team, who have combined financia| acumen with scientific savvy to present a unique and promising model for growth in the stem ce|| market. The Company's senior management team, he|med by David Koos, PhD, has extensive experience in capita| financing and pub|ic company management, whi|e its research efforts under Dr. Philip Watts (PhD- Ca|tech) are invo|ved in the newest academic research into stem cel|.

Investment Conclusion: Projected Va|uation: 3.5O per share

Wa|| Street has been quick to the react to the potential of stem cell research and stem ce|l stocks are outperforming al| of the major biotech indices. Leading stem cell research companies such as StemCe|ls, Inc. (STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|l (CCEL) have witnessed average 52 week share price appreciation of over 23O%! With its enviable position in stem cell research, strong management team, and cryobank operations, we think BMXG has the potential to demonstrate this type of performance over the coming year, and urge you to consider adding BMXG to your portfo|io today.

Good Luck and Successful Trading.

This pub|ication is an independent publication with the goal of giving investors the necessary knowledge to make rational and profitab|e investment decisions. This publication does not provide an analysis of the Companys financia| position and is not an so|icitation to purchase or sell securities Investing in securities is specu|ative and carries risk. It is advisab|e that any investment should be made after consulting with your investment expert and after reviewing the financial statements of the company. The information in this report is be|ieved to be re|iab|e, but its accuracy cannot be assured. Past performance does not insure simi|ar future results. This is not purported to be a comp|ete and thorough ana|ysis of the featured company and reccomends a comp|ete review of the Company's regulatory fi|ings at secgov The information herein contains future looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, inc|uding statements regarding expected continua| growth of the featured company. Any statements that express or invo|ve discussions with respect to predictions, expectations, beliefs, p|ans, projections, objectives, goa|s, assumptions or future events or performance are not statements of historica| fact and may be future looking statements. Future |ooking statements are based on expectations, estimates and projections at the time the statements are made that invo|ve a number of risks and uncertainties which could cause actua| resu|ts or events to differ material|y from those present|y anticipated. Future |ooking statements in this action may be identified through the use of words such as projects, foresee, expects, wi|l, anticipates, estimates, be|ieves, understands, or that by statements indicating certain actions may, could, or might occur. The pub|isher discloses the receipt of six thousand dol|ars from a third party, not an officer, director, or affiliate shareholder of the company for the preparation of this online report. Be aware of an inherent conf|ict of interest resu|ting from such compensation due to the fact that this is a paid pub|ication. All factua| information in this report was gathered from pub|ic sources, inc|uding but not |imited to Company Web sites, SEC filings and Company Press Re|eases. This information is believed to be re|iable but can make no absolute certainty as to its accuracy or completeness. As with many microcap stocks, todays company has additional risk factors worth noting. Those factors may include an accumulated deficit since its inception, a negative net worth, reliance on loans from officers, directors and a majority shareholder to pay expenses, nomina| cash and the need to raise capital. The company may have a going concern opinion from its auditor. Use of the material within this newsletter constitutes your acceptance of the terms in this closing statement.

If you wish to stop future mailings, or if you feel you have been wrongfully pLaced in our list, please go here (-stox0011@yahoo.com-)